← The record

Umeclidinium Bromide And Vilanterol TrifenatateAnoro Ellipta

Not recommended RespiratoryRestrictedLater-line line

Treatment of chronic obstructive pulmonary disease (COPD) in adults where symptoms persist despite regular bronchodilator treatment with a long acting muscarinic antagonist (LAMA) and/or long acting beta2 agonist (LABA), or in patients stabilised on a combination of LAMA and LABA in separate devices.

1
Submissions
2014–14
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. TGA registered · Anoro Ellipta

    TGA label narrower than the PBS population

  2. Mar 2014
    Not recommended

    Absence of individual components (umeclidinium and vilanterol) on PBS is problematic for stepwise treatment; risks of…

RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC rejected the submission requesting PBS-listing for UMEC/VI FDC for the treatment of COPD. The PBAC considered that the cost-minimisation approach used, where the price of the FDC was cost-minimised to the sum of the prices of indacaterol plus tiotropium was not justified by the evidence presented in the submission.PSD · Mar 2014
7.2 The PBAC also considered that having a combination product available without having the individual components available was problematic. Patients with COPD cannot be treated in the stepwise manner recommended without changing the LABA and LAMA medications.PSD · Mar 2014
Economic analysis
6.26 The submission presented a cost-minimisation analysis based on the non-inferiority claim versus tiotropium plus indacaterol. The equi-effective doses were estimated as UMEC/VI 62.5/25 micrograms and tiotropium 18 micrograms plus indacaterol 150 micrograms. A summary of the cost-minimisation analysis is presented in the table below. 8PSD · Mar 2014
Clinical claim
6.22 The submission claimed that UMEC/VI combination therapy has comparable effectiveness to indacaterol (150 µg) plus tiotropium (18 µg) at 12 weeks. The submission also claimed that UMEC/VI combination therapy is non-inferior in terms of efficacy to indacaterol/glycopyrronium (110/50 micrograms).PSD · Mar 2014
6.23 The submission claimed that UMEC/VI combination therapy has a mostly benign and similar safety profile to indacaterol plus tiotropium, and is non-inferior in terms of safety to indacaterol/glycopyrronium.PSD · Mar 2014

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated by design

The PBAC agreed with the ESC that having a combination product available without having the individual components available was problematic. PBAC · 2014
Economic model disputed

Decision context

PopulationAdult patients with COPD where symptoms persist despite regular bronchodilator treatment with LAMA and/or LABA, or patients stabilised on combination LAMA and LABA in separate devices

Why it was knocked back

  • Absence of individual components (umeclidinium and vilanterol) on PBS is problematic for stepwise treatment; risks of inappropriate early combination therapy transition and potential double-dosing of LABAs; no superiority demonstrated over comparator on clinically relevant outcomes; concerns regarding safety profile with higher adverse event and serious adverse event rates in some trials; safety risks from potential prescribing errors and incorrect dosing of FDC products

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2014 Not recommended tiotropium plus indacaterol RCT · Surrogate

Clinical evidence

Trials cited in the PSDs · ClinicalTrials.gov
TrialPhaseNPrimary outcomeStatus
DB2113361 Ph 3 1,493 Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 1… completed

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricted to patients with persistent symptoms despite LAMA and/or LABA treatment; TGA label has no prior treatment requirement.